123 related articles for article (PubMed ID: 18342791)
21. Paediatric Hodgkin lymphoma with Reed-Sternberg and mononuclear Hodgkin cells in the bone marrow aspirate.
Swart L; Shuttleworth MH; Opie JJ; van Schalkwyk WA
Br J Haematol; 2012 Apr; 157(1):2. PubMed ID: 22329501
[No Abstract] [Full Text] [Related]
22. Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
Borchmann P
Hematol Oncol Clin North Am; 2014 Feb; 28(1):65-74. PubMed ID: 24287068
[TBL] [Abstract][Full Text] [Related]
23. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
24. Hodgkin's lymphoma with cutaneous involvement.
Dhull AK; Soni A; Kaushal V
BMJ Case Rep; 2012 Nov; 2012():. PubMed ID: 23195828
[TBL] [Abstract][Full Text] [Related]
25. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
26. Treatment of advanced stage Hodgkin lymphoma--it's all about risk-benefit.
Phipps C; Lee YS; Hwang W
Br J Haematol; 2012 Oct; 159(1):113-5. PubMed ID: 22823109
[No Abstract] [Full Text] [Related]
27. Membranous glomerulonephritis in a patient with Hodgkin's lymphoma in remission.
Sánchez M; Enríquez R; Sirvent AE; Heredia L; Millán I; Amorós F
Nefrologia; 2013; 33(5):745-7. PubMed ID: 24089174
[No Abstract] [Full Text] [Related]
28. PET-CT: reliable cornerstone for Hodgkin lymphoma treatment?
Zijlstra JM
Blood; 2016 Mar; 127(12):1521-2. PubMed ID: 27013209
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
30. Unusual manifestation of Hodgkin disease.
Dunlap N; Parkhie S
Am J Clin Oncol; 2006 Oct; 29(5):529-30. PubMed ID: 17023792
[No Abstract] [Full Text] [Related]
31. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
[TBL] [Abstract][Full Text] [Related]
32. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
[TBL] [Abstract][Full Text] [Related]
33. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
Evens AM; Cilley J; Ortiz T; Gounder M; Hou N; Rademaker A; Miyata S; Catsaros K; Augustyniak C; Bennett CL; Tallman MS; Variakojis D; Winter JN; Gordon LI
Br J Haematol; 2007 Jun; 137(6):545-52. PubMed ID: 17459049
[TBL] [Abstract][Full Text] [Related]
34. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.
Stamatoullas A; Brice P; Bouabdallah R; Mareschal S; Camus V; Rahal I; Franchi P; Lanic H; Tilly H
Br J Haematol; 2015 Jul; 170(2):179-84. PubMed ID: 25891777
[TBL] [Abstract][Full Text] [Related]
35. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
[TBL] [Abstract][Full Text] [Related]
36. Increased relapse rates in early stage hodgkin lymphoma (HL) patients without radiotherapy: the German Society of Radiooncology (DEGRO) advises to treat all early stage HL patients with radiotherapy.
Körholz D; Mauz-Körholz C; Vordermark D; Kluge R; Dieckmann K
Klin Padiatr; 2014 Nov; 226(6-7):307-8. PubMed ID: 25431863
[No Abstract] [Full Text] [Related]
37. Presentation of Hodgkin's lymphoma with Ophelia syndrome.
Olmos D; Rueda A; Jurado JM; Alba E
J Clin Oncol; 2007 May; 25(13):1802-3. PubMed ID: 17470872
[No Abstract] [Full Text] [Related]
38. Acquired Glanzmann thrombasthenia associated with Hodgkin lymphoma: rapid reversal of functional platelet defect with ABVD (adriamycin/bleomycin/vinblastine/dacarbazine) chemotherapy.
Raman V; Quillen K; Sloan JM
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e51-4. PubMed ID: 24342105
[No Abstract] [Full Text] [Related]
39. Uncommon presentations of Hodgkin's disease. Case 2. Hodgkin's disease of the nasopharynx.
Hollander SL
J Clin Oncol; 2004 Jan; 22(1):195-6. PubMed ID: 14701783
[No Abstract] [Full Text] [Related]
40. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?
Canellos GP; Duggan D; Johnson J; Niedzwiecki D
J Clin Oncol; 2004 Apr; 22(8):1532-3. PubMed ID: 15084636
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]